ClinicalTrials.gg
CompletedNCT01499563Updated Oct 3, 2025Results posted

Study of a Novel Antipsychotic ITI-007 in Schizophrenia

A Phase 2 interventional study of ITI-007 and Placebo in Schizophrenia, sponsored by Intra-Cellular Therapies, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
335
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing lumateperone in Schizophrenia — 3 open to participants now, 3 under way, 2 of them phase 3. lumateperone · Schizophrenia.

Enrollment
4th of 12
335 · median 66
Started
2011
the only one that year
Phase 2
3 of 12
none open now
Registered
1st of 12
by date
Lead sponsor
9 of 12
Intra-Cellular Therapies, Inc.

Among the 12 studies testing lumateperone in Schizophrenia, this one is the 4th largest by enrollment, is the only one that started in 2011, is one of 3 in phase 2, and was the 1st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 12 studies testing lumateperone in Schizophrenia are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lumateperone

lumateperone: first FDA approval 2019 (CAPLYTA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing lumateperone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether ITI-007 is effective in reducing symptoms associated with schizophrenia in patients who are having an acute worsening of their psychosis. Patients will be randomly assigned to receive one of two doses of ITI-007, placebo, or a positive control. The primary goal will be to assess the effects of ITI-007 on psychosis. The safety of ITI-007 will also be assessed.

Read the detailed description

The study will be conducted as a randomized, double-blind, placebo-controlled, multi-center study in patients diagnosed with schizophrenia and an acute exacerbation of psychosis. The efficacy and safety of two dose levels of ITI-007 administered daily for 28 days will be evaluated as compared to placebo; risperidone has been included as a positive control.

Upon completion of the inpatient 28-day Study Treatment Period, patients will be started on standard antipsychotic medication and will be stabilized over a 5-day period before discharge from the study clinic. Patients will be seen for a final outpatient safety evaluation at the End-of-Study visit approximately 2 weeks after discharge.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient's age is 18-55
  • Patient has current diagnosis of schizophrenia and is experiencing an acute exacerbation of psychosis
  • Patient has a history of at least three months exposure to one or more antipsychotic therapy(ies) and a prior response to antipsychotic therapy within the previous five years

Exclusion criteria

Exclusion Criteria:

  • Any female patient who is pregnant or breast-feeding
  • Any patient presenting with concurrent dementia, delirium, mental retardation, epilepsy, drug-induced psychosis, or history of significant brain trauma
  • Any patient presenting with schizoaffective disorder, bipolar disorder, acute mania, or major depression with psychotic features
  • Any patient considered to be an imminent danger to themselves or others
  • Any patient with hematological, renal, hepatic, endocrinological, neurological, or cardiovascular disease or substance abuse as defined by protocol
  • Any patient judged by the Investigator to be inappropriate for the study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
335 participants (actual)

Study arms

  • Experimental
    ITI-007 Low Dose

    Lumateperone 42 mg (ITI-007 60 mg tosylate) administered for 28 days

    Drug: ITI-007 · Drug: Placebo

  • Experimental
    ITI-007 High Dose

    Lumateperone 84 mg (ITI-007 120 mg tosylate) administered for 28 days

    Drug: ITI-007

  • Placebo comparator
    Placebo

    Placebo: Capsules containing inactive placebo administered for 28 days

    Drug: Placebo

  • Active comparator
    Risperidone

    Risperidone: Capsules containing 4 mg risperidone administered for 28 days

    Drug: Risperidone

Interventions

  • Capsules containing ITI-007 for 28 days

  • DrugPlacebo

    Capsules containing inactive placebo for 28 days

  • Capsules containing risperidone for 28 days

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.

    Time frame: Change from baseline to Day 28

Secondary outcomes

  1. Change From Baseline to Day 8 in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.

    Time frame: Change from Baseline to Day 8

  2. Change From Baseline to Day 15 in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.

    Time frame: Change from Baseline to Day 15

  3. Change From Baseline to Day 22 in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.

    Time frame: Change from Baseline to Day 22

07

Results

Posted Oct 3, 2025

Participant flow

Participant flow — Overall Study
MilestoneLumateperone 42 mg (ITI-007 60 mg Tosylate)Lumateperone 84 mg (ITI-007 120 mg Tosylate)PlaceboRisperidone 4 mg
Started84838582
Completed60646163
Not completed24192419
Withdrew: Withdrawal by subject101178
Withdrew: Physician decision2130
Withdrew: Specific request of sponsor or investigator2011
Withdrew: Adverse event2013
Withdrew: Lack of efficacy0163
Withdrew: Other8664

Outcome measures

PrimaryChange From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.

Time frame:
Change from baseline to Day 28
Reported as:
Least squares mean · score on a scale
Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score
score on a scaleLumateperone 42 mg (ITI-007 60 mg Tosylate)Lumateperone 84 mg (ITI-007 120 mg Tosylate)PlaceboRisperidone 4 mg
Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score-13.2 ± 1.7-8.3 ± 1.7-7.4 ± 1.7-13.4 ± 1.7
Statistical analysis
  • Lumateperone 42 mg (ITI-007 60 mg Tosylate) vs Placebo · Mixed Effects model for Repeated Measure · p = 0.017 · Least squares mean difference: -5.8 · 95% CI -11.1 to -0.495% CI for LS Mean difference are with Bonferroni correction
  • Lumateperone 84 mg (ITI-007 120 mg Tosylate) vs Placebo · Mixed Effects Model for Repeated Measure · p = 0.708 · Least squares mean difference: -0.9 · 95% CI -6.3 to 4.595% CI for LS Mean difference are with Bonferroni correction
SecondaryChange From Baseline to Day 8 in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.

Time frame:
Change from Baseline to Day 8
Reported as:
Least squares mean · units on a scale
Change From Baseline to Day 8 in Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scaleLumateperone 42 mg (ITI-007 60 mg Tosylate)Lumateperone 84 mg (ITI-007 120 mg Tosylate)PlaceboRisperidone 4 mg
Change From Baseline to Day 8 in Positive and Negative Syndrome Scale (PANSS) Total Score-4.0 ± 1.2-4.7 ± 1.2-2.6 ± 1.2-6.3 ± 1.2
SecondaryChange From Baseline to Day 15 in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.

Time frame:
Change from Baseline to Day 15
Reported as:
Least squares mean · units on a scale
Change From Baseline to Day 15 in Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scaleLumateperone 42 mg (ITI-007 60 mg Tosylate)Lumateperone 84 mg (ITI-007 120 mg Tosylate)PlaceboRisperidone 4 mg
Change From Baseline to Day 15 in Positive and Negative Syndrome Scale (PANSS) Total Score-7.8 ± 1.4-4.2 ± 1.3-4.5 ± 1.3-9.6 ± 1.4
SecondaryChange From Baseline to Day 22 in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.

Time frame:
Change from Baseline to Day 22
Reported as:
Least squares mean · units on a scale
Change From Baseline to Day 22 in Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scaleLumateperone 42 mg (ITI-007 60 mg Tosylate)Lumateperone 84 mg (ITI-007 120 mg Tosylate)PlaceboRisperidone 4 mg
Change From Baseline to Day 22 in Positive and Negative Syndrome Scale (PANSS) Total Score-10.5 ± 1.6-6.6 ± 1.5-4.6 ± 1.5-10.8 ± 1.6

Adverse events

Collected over From signing ICF until end of study procedures (~ weeks) including 28 days of double-blind treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lumateperone 42 mg (ITI-007 60 mg Tosylate)0/84 (0%)0/84 (0%)39/84 (46.4%)
Lumateperone 84 mg (ITI-007 120 mg Tosylate)0/83 (0%)0/83 (0%)52/83 (62.7%)
Placebo0/85 (0%)1/85 (1.2%)28/85 (32.9%)
Risperidone 4 mg0/82 (0%)1/82 (1.2%)37/82 (45.1%)
Most frequent serious events
Most frequent serious events
EventLumateperone 42 mg (ITI-007 60 mg Tosylate)Lumateperone 84 mg (ITI-007 120 mg Tosylate)PlaceboRisperidone 4 mg
Psychotic disordersPsychiatric disorders0/840/830/851/82
SchizophreniaPsychiatric disorders0/840/831/850/82
Most frequent other events
Showing 10 of 11
Most frequent other events
EventLumateperone 42 mg (ITI-007 60 mg Tosylate)Lumateperone 84 mg (ITI-007 120 mg Tosylate)PlaceboRisperidone 4 mg
SedationNervous system disorders6/8417/836/855/82
HeadacheNervous system disorders17/8415/8311/857/82
SomnolenceNervous system disorders8/8411/835/8512/82
Blood Creatine Phosphokinase IncreasedInvestigations7/843/831/858/82
DizzinessNervous system disorders5/848/831/851/82
NauseaGastrointestinal disorders6/848/831/854/82
Dry MouthGastrointestinal disorders4/848/832/855/82
AkathisiaNervous system disorders1/842/832/856/82
Weight IncreasedInvestigations5/845/836/855/82
DyspepsiaGastrointestinal disorders5/841/831/853/82

Baseline characteristics

All Baseline data are presented for patients who received at least one dose of study drug, with the exception of the PANSS total score which is presented for patients who received at least 4 doses of study drug and who had a baseline measurement as well as at least 1 valid post-baseline efficacy measurement.

Age, Continuous
Age, Continuous(years)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Lumateperone 84 mg (ITI-007 120 mg Tosylate)PlaceboRisperidone 4 mgTotal
Mean38.3 ± 10.0341.4 ± 8.9240.5 ± 9.8340.7 ± 9.3340.1 ± 9.56
Sex: Female, Male
Sex: Female, Male(Participants)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Lumateperone 84 mg (ITI-007 120 mg Tosylate)PlaceboRisperidone 4 mgTotal
Female181120958
Male66726573276
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Lumateperone 84 mg (ITI-007 120 mg Tosylate)PlaceboRisperidone 4 mgTotal
Caucasian/White1316171662
Black or African American70626564261
Asian00123
Other15309
Positive and Negative Syndrome Scale (PANSS) Total Score
Positive and Negative Syndrome Scale (PANSS) Total Score(units on a scale)Lumateperone 42 mg (ITI-007 60 mg Tosylate)Lumateperone 84 mg (ITI-007 120 mg Tosylate)PlaceboRisperidone 4 mgTotal
Mean88.1 ± 11.0484.6 ± 11.6386.3 ± 13.1086.1 ± 12.2486.2 ± 12.04
08

Study locations

8 sites
  • Clinical Site
    Little Rock, Arkansas, United States
  • Clinical Site
    Garden Grove, California, United States
  • Clinical Site
    Atlanta, Georgia, United States
  • Clinical Site
    Rockville, Maryland, United States
  • Clinical Site
    St Louis, Missouri, United States
  • Clinical Site
    Willingboro, New Jersey, United States
  • Clinical Site
    Philadelphia, Pennsylvania, United States
  • Clinical Site
    Austin, Texas, United States
09

References and documents

Publications

  • Citrome L, Durgam S, Edwards JB, Davis RE. Lumateperone for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed. J Clin Psychiatry. 2023 Mar 6;84(2):22r14631. doi: 10.4088/JCP.22r14631. PubMed 36883881 ↗
  • Lieberman JA, Davis RE, Correll CU, Goff DC, Kane JM, Tamminga CA, Mates S, Vanover KE. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. Biol Psychiatry. 2016 Jun 15;79(12):952-61. doi: 10.1016/j.biopsych.2015.08.026. Epub 2015 Aug 31. PubMed 26444072 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Aug 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2025, 12 years 2 months after primary completion. A results delay was requested in Sep 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2011
First posted
Dec 26, 2011
Start
Dec 2011
Primary completionActual
Aug 2013
CompletionActual
Nov 2013
Results delay requested
Sep 3, 2014
Results first posted
Oct 3, 2025
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01499563
Responsible party
Sponsor
First posted
Dec 26, 2011
Start date
Dec 2011
Primary completion
Aug 2013
Completion
Nov 2013
Results posted
Oct 3, 2025
Last update
Oct 3, 2025

Study contacts

Kimberly E Vanover, PhD
study director · Intra-Cellular Therapies

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion